Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes
- 10 November 2006
- journal article
- research article
- Published by Elsevier BV in Antiviral Research
- Vol. 73 (3), 228-231
- https://doi.org/10.1016/j.antiviral.2006.10.004
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug designNature, 2006
- Distribution of Amantadine‐Resistant H5N1 Avian Influenza Variants in AsiaThe Journal of Infectious Diseases, 2006
- Antivirals for influenza: Historical perspectives and lessons learnedAntiviral Research, 2006
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- Neuraminidase Inhibitor-Resistant and -Sensitive Influenza B Viruses Isolated from an Untreated Human PatientAntimicrobial Agents and Chemotherapy, 2006
- Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United StatesJAMA, 2006
- Mallards and Highly Pathogenic Avian Influenza Ancestral Viruses, Northern EuropeEmerging Infectious Diseases, 2005
- Molecular mechanisms of influenza virus resistance to neuraminidase inhibitorsVirus Research, 2004
- Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivirAntiviral Research, 2004
- Developing vaccines against pandemic influenzaPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2001